Farmacogenómica en el cáncer colorrectal
- Bandrés, E.
- Zabalegui, N.
- Zarate, Ruth
- Catalán, V.
- Honorato, B.
- García, F.
- Andión, E.
- Escalada, A.
- Martín-Algarra, S.
- Garcia Foncillas, Jesús
Datum der Publikation: 2003
Ausgabe: 47
Nummer: 1
Seiten: 39-45
Art: Artikel
Zusammenfassung
Advances in human genome research will make it possible to personalize pharmacotherapy. Pharmacogenomics has been defined as the study of mechanisms that explain how an individual's genetic inheritance affects the response to drugs. The ability to predict which therapies are most likely to be effective for certain patients would constitute a powerful medical tool, particularly in oncology. Such predictions would be likely to arise from an understanding of the disease on the cellular and molecular level. For colorectal cancer, our increased knowledge of the molecular etiology of the disease has not yet been paralleled by an improvement in patient care. Clinical efficacy and also toxicity of a given chemotherapy are still largely unpredictable for the individual patient. Amongst other variables, genetic polymorphisms determine the interindividual heterogeneity in both toxicity and therapeutic efficacy. Due to the better molecular characterization of colorectal cancer and the development of new target-directed therapies, it should be possible to predict which therapeutic interventions will have a high likelihood of success for an individual patient.